On September 18, CANSINOBIO rose 6.86% in regular trading, trading at HKD 27.0/share, with turnover of HKD 42.41 million.

On the news front, the company's latest interim results showed H1 revenue of approximately RMB 5.47 billion, up 46.1% year-over-year. Operating profit reached RMB 27.54 million, achieving a turnaround from the prior-year operating loss of RMB 2.21 million. Adjusted net loss narrowed sharply to just RMB 721,000 from RMB 13.49 million a year earlier. Gross margin remained elevated at 75.6%. Notably, overseas revenue surged 4,724.19% year-over-year to RMB 152 million, reflecting accelerating internationalization through product exports, intermediate supply, technology transfer, and joint clinical development.

Additionally, on September 16, the board granted 287,400 restricted A-shares to 19 eligible employees at RMB 41.20 per share under the 2025 equity incentive plan, signaling management confidence in the company's growth trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)